China Universal Asset Management Company’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

China Universal Asset Management Company’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-644	Closed	-$69.1K	–	464
2023 Q1	$69.1K	Buy	644 +218	+51%	+$25.1K	0.02%	143
2022 Q4	$46.9K	Buy	426 +43	+11%	+$2.79K	0.02%	139
2022 Q3	$23K	Buy	+383	New	+$17.5K	0.01%	149

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

China Universal Asset Management Company's RXDX Position: Q2 2023 in Review

China Universal Asset Management Company sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 644 shares — an estimated $69.1K sold.

China Universal Asset Management Company first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $69.1K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

China Universal Asset Management Company reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
China Universal Asset Management Company sold 644 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $69.1K.
China Universal Asset Management Company first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
China Universal Asset Management Company's Prometheus Biosciences, Inc. Common Stock position peaked at $69.1K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on China Universal Asset Management Company's 13F filing for Q2 2023, filed 28 Jul 2023.